UNC at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
NCT Number: NCT03419364
Phase II Study of 2.5 gm of nicotinamide, given daily in 3 divided doses, to measure effect on maternal blood pressure in women with early onset preeclampsia and to determine peak and trough levels of nicotinamide. We will compare peak and trough levels in healthy non-pregnant and healthy pregnant participants.
Looking for future studies?
Notify Me18 year–55 year
Female
Interventional
Phase 2
Chapel Hill, North Carolina, 27599, United States
See brief summary above
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Diagnosis and Inclusion Criteria
Exclusion criteria
2.5 gm nicotinamide given orally in 3 divided doses: 1000 mg in morning and evening, 500 mg at noon/midday
Other names: niacinamide
Time frame: Baseline, 48 hours
Blood pressure (mmHg) will be used to observe the effect of nicotinamide. The highest MAP (defined as the highest MAP within the 24 hour period prior to the administration of study agent) and the highest MAP through 24 hours after study drug administration.
Time frame: Within 24 hours of any dose, up to a maximum 4 weeks
Time frame: Within 24 hours of any dose, up to a maximum 4 weeks
Time frame: From initial administration of study agent until 24 hours post last dose, up to a maximum of 4 weeks
Maternal side effects are defined as: facial erythema, hives, sore mouth, dry hair, fatigue, flushing, headache, nausea, and heart burn.
Time frame: From initial administration of study agent until 24 hours post last dose, up to a maximum of 4 weeks
Time frame: From initial administration of study agent until 24 hours post last dose, up to a maximum of 4 weeks
Time frame: From initial administration of study agent until 24 hours post last dose, up to a maximum of 4 weeks
Time frame: From initial administration of study agent until 24 hours post last dose, up to a maximum of 4 weeks
Time frame: From initial administration of study agent until 24 hours post last dose, up to a maximum of 4 weeks
A Non Stress Test is a determination of the current well-being of the fetus, as measured by the fetal heart rate. Category I indicates that the fetus is in a state of well-being and is tolerating the intrauterine environment. Category II indicates a fetal heart rate that is showing some signs of distress. In this instance, obstetric providers will try to improve the intrauterine environment to allow the pregnancy to continue. Category III relates to a fetus whose well-being is compromised - usually requiring rapid intervention, ie expedient delivery.
Time frame: From initial administration of study agent until 24 hours post last dose
Time frame: at 1 hour post 1000 mg nicotinamide administration on Day 1
The mean was calculated for each group using blood samples drawn on Day 1 at 1 hour post 1000 mg nicotinamide administration routinely given at 8 a.m. Peak nicotinamide level expected at 1 hour post dose.
Time frame: 8 hours after the 8 a.m. 1000 mg nicotimamide administration on Day 1
The mean was calculated for each group for blood samples drawn on Day 1 8 hours post 1000 mg nicotinamide administration routinely given at 8 a.m. Trough nicotinamide level is measured immediately prior to the next dose.
University of North Carolina, Chapel Hill
Other
Phase II Study of Nicotinamide in Early Onset Preeclampsia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06640842
Alzheimer Disease, Brain Diseases
Kansas City, Kansas, United States
View Trial DetailsNCT05142410
Female Urogenital Diseases and Pregnancy Complications, Hypertension, Pregnancy-Induced
Nîmes, Gard, France
View Trial DetailsNCT03232762
Behavior, Birth Weight
New York, United States
View Trial DetailsNCT06417411
Anemia, Anemia, Hemolytic
Luanda, Luanda Province, Angola
View Trial Details